ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide [Yahoo! Finance]
ChromaDex Corporation (CDXC)
NASDAQ:AMEX Investor Relations:
investors.chromadex.com
Company Research
Source: Yahoo! Finance
LOS ANGELES, November 07, 2024 BUSINESS WIRE ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, today announced the nationwide rollout of its pharmaceutical-grade nicotinamide riboside chloride (NRC) products, Niagen® IV , now accessible at over 200 Restore Hyper Wellness locations across the United States. This represents a major milestone, making Niagen IV—a significant advancement in intravenous NAD+ therapy—more widely accessible to wellness enthusiasts looking to enhance cellular health and extend their healthspan. Available in oral and IV forms, ChromaDex's clinically proven patented ingredient, Niagen, is the most efficient, high-quality NAD+ precursor available. NAD+ is a coenzyme that powers cells and supports metabolic processes throughout the body, yet it declines with age and due to everyday stressors like sun exposure, high-fat diets, overtraining, and sedentary lifestyles—a decline li
Show less
Read more
Impact Snapshot
Event Time:
CDXC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CDXC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CDXC alerts
High impacting ChromaDex Corporation news events
Weekly update
A roundup of the hottest topics
CDXC
News
- Recent Price Trend in ChromaDex (CDXC) is Your Friend, Here's Why [Yahoo! Finance]Yahoo! Finance
- ChromaDex Co. (NASDAQ: CDXC) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- ChromaDex's Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology's Inaugural Longevity Supplement [Yahoo! Finance]Yahoo! Finance
- ChromaDex’s Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology’s Inaugural Longevity SupplementBusiness Wire
- ChromaDex Co. (NASDAQ: CDXC) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
CDXC
Earnings
- 10/31/24 - Beat
CDXC
Sec Filings
- 11/21/24 - Form 8-K
- 11/8/24 - Form 3
- 10/31/24 - Form 8-K
- CDXC's page on the SEC website